Led data analytics and customer sales performance reviews while executing various organizational strategies, business development, and partnership projects.Delivered Results:▪ Developed dynamic sales and commercial product performance dashboard to elevate business decisions, improving country pharma office bottom line and reducing manual effort. ▪ Designed new processes and implemented agile methodologies, avoiding demand, and forecast volatility caused in supply chain and financial planning departments due to COVID-19 pandemic.▪ Automated external data clean-up processes using Power Queries, Alteryx workflow, reducing time from 1.5 days to 5 minutes and meeting data and digital objectives while working relentlessly and collaboratively to bring efficiencies in distributor performance metrics.▪ Collaborated with Business Planning & Analysis group in monthly assessments of channel performance and maintained healthy working relations with all stakeholders across multiple therapeutic areas.

Managed roll out of transparency reporting processes to 46+ global markets whilst developing specialist knowledge on all reportable financial spend data, IT systems and related regulations.Delivered Results: ▪ Managed 11 associates with yearly objective setting, performance reviews and growth aspects, maintaining excellent client satisfaction scores of 4.6 out of 5.0 between Q3’18 to Q3’19 and meeting Service Level Agreements.▪ Developed lean methods to gather, cleanse, structure data from various source systems for quality end to end financial data disclosure for FY’2018 - FY’19▪ Prepared and presented key insights to executive team on various market trends on HCPs, HCOs, and Patient Groups engagements, allowing organizational alignment with EFPIA and US Sunshine ACT ▪ Tracked project progress against plan, quickly identifying and resolving issues with effective corrective actions. ▪ Steered efforts in implementing new technologies, including Qlik-sense, Tableau to automate reports and data visualization, yielding overall 2 FTE savings between 2017-18

Supported Sandoz Bio-Pharma group through business projects and initiative implementation leveraged to improve product competitiveness. Delivered productive revenue generation efforts for North American region.• Implemented comprehensive performance tracker for top bio-pharma products and helped marketing and brand teams to assess wholesaler multi-channel performance.• Introduced monthly customer performance deck on product net sales vs target, YTD % to TGR, and % of Gap to target, focusing on top wholesalers.• Provided services through structured project management approach with appropriate documentation and communication throughout delivery of services, winning Above and Beyond recognition.

Managed overall Trial Finance Operations for assigned global clinical studies and participating clinical sites and vendors.• Collaborated with Medical Franchise Clinical Teams to coordinate, track, and generate payment requests for clinical trials, managing overall site budget against assigned studies.• Delivered seamless results by managing project spend reconciliations throughout project life cycle i.e. from study start up to data base lock.• Assisted in successful internal and external audits through sound and thorough documentation practice.• Recognized with business excellence STAR award for implementing new work stream that defined and instigated latest directions, roles, and responsibilities for Global Trial Finance and Operations group in 2014.

Reported to Area Manager Finance Operational Services and led Accounts Receivable team within Global Financial Services with credit and collections activities for small and medium business unit.• Planned, supervised, and coordinated daily tasks for 6 AR associates and helped in processing of invoices, reconciliation of accounts, cash applications, and monthly / yearly performance reviews.• Received special recognition award in 2010 by VP of Global Financial Services for exemplary performance; recognized for the efforts applied in handling the Canadian Public Segment portfolio comprising of $65M.